Neoadjuvant Nivolumab and Relatlimab in Merkel Cell Carcinoma

Conditions: Merkel Cell Carcinoma Interventions: Drug: Nivolumab 240 mg / Relatlimab 80 mg in a fixed dose combination Sponsors: Melanoma Institute Australia; Bristol-Myers Squibb Not yet recruiting

https://clinicaltrials.gov/study/NCT06151236

Source: ClinicalTrials.gov - November 30, 2023 Category: Research Source Type: clinical trials